Overview

Phase 2 AMG 714 in Rheumatoid Arthritis

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Twelve week treatment of AMG 714 in RA patients who failed at least one DMARD, followed by a 3 month observational period.
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Treatments:
Antirheumatic Agents